Research publications | Alfred Health

Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method

Chen GB, Lee SH, Montgomery GW, Wray NR, Visscher PM, Gearry RB, Lawrance IC, Andrews JM, Bampton P, Mahy G, Bell S, Walsh A, Connor S, Sparrow M, Bowdler LM, Simms LA, Krishnaprasad K; International IBD Genetics Consortium, Radford-Smith GL, Moser G

(2017), BMC Med Genet, 18, 94

DOI: 10.1186/s12881-017-0451-2

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Vermeire S, Sandborn WJ, Danese S, H»buterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, GreguŠ M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W

(2017), Lancet, 390(10090), 135-44

DOI: 10.1016/S0140-6736(17)30930-3

Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease

Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ

(2017), Inflamm Bowel Dis, 23(7), 1240-6

DOI: 10.1097/MIB.0000000000001136

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target

Sparrow MP

(2017), Expert Opin Biol Ther, 17(5), 613-21

DOI: 10.1080/14712598.2017.1309390

Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply

Ward MG, Gibson PR, Sparrow MP

(2017), Aliment Pharmacol Ther, 45(11), 1476-7

DOI: 10.1111/apt.14091

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline

Su HY, Ward MG, Sparrow MP

(2017), Transl Gastroenterol Hepatol, 2, 113

DOI: 10.21037/tgh.2017.12.05

Is there a role for thioguanine therapy in IBD in 2017 and beyond?

Taylor KM, Ward MG, Blaker PA, Sparrow MP

(2017), Expert Rev Gastroenterol Hepatol, 11(5), 473-86

DOI: 10.1080/17474124.2017.1294062

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies

Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mâki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP

(2017), Lancet Gastroenterol Hepatol, 2(7), 479-93

DOI: 10.1016/S2468-1253(17)30110-3

Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool

Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, Williams SJ, Zanati S, Byth K, Bourke MJ

(2017), Gastrointest Endosc, 85(3), 647-56.e6

DOI: 10.1016/j.gie.2016.11.027

Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse

Aggarwal V, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI

(2017), Gastrointest Endosc, 86(6), 1070-8

DOI: 10.1016/j.gie.2017.09.011

Hepatobiliary and pancreatic: hepatic and mesenteric aneurysms with biloma formation

Ling QA, Yo J, Gerstenmaier JF, Kemp W

(2017), J Gastroenterol Hepatol, 32(6), 1134

DOI: 10.1111/jgh.13765

Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review

Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D

(2017), J Gastroenterol Hepatol, 32(8), 1426-35

DOI: 10.1111/jgh.13750

Hepatobiliary and pancreatic: rare vascular tumor following treatment for hepatitis C with direct-acting antivirals

Britto K, Cheung W, Cameron R, Roberts SK, Kemp W

(2017), J Gastroenterol Hepatol, 32(12), 1912

DOI: 10.1111/jgh.13916

Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: a large multicentre cohort study

Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK

(2017), J Viral Hepat, 24(11), 982-9

DOI: 10.1111/jvh.12717

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R

(2017), Lancet Gastroenterol Hepatol, 2(11), 805-13

DOI: 10.1016/S2468-1253(17)30159-0

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

BourliÀre M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de L»dinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators

(2017), N Engl J Med, 376(22), 2134-46

DOI: 10.1056/NEJMoa1613512

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study

Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN)

(2017), Antivir Ther, 22(8), 699-710

DOI: 10.3851/IMP3168

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Polaris Observatory HCV Collaborators

(2017), Lancet Gastroenterol Hepatol, 2(3), 161-76

DOI: 10.1016/S2468-1253(16)30181-9

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Brâu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR

(2017), Gastroenterology, 153(1), 113-22

DOI: 10.1053/j.gastro.2017.03.047

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P

(2017), Liver Int, 37(6), 827-35

DOI: 10.1111/liv.13331